[{"orgOrder":0,"company":"SMSbiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"SMSbiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Suspension for Nebulizer","sponsorNew":"SMSbiotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SMSbiotech \/ Inapplicable"},{"orgOrder":0,"company":"SMSbiotech","sponsor":"USAMRICD","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"SMSbiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SMSbiotech \/ USAMRICD","highestDevelopmentStatusID":"1","companyTruncated":"SMSbiotech \/ USAMRICD"},{"orgOrder":0,"company":"SMSbiotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Stem Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"SMSbiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SMSbiotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SMSbiotech \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by SMSbiotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Stem Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          May 22, 2025

                          Lead Product(s) : Stem Cell

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under theagreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 22, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : USAMRICD

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Small Mobile stem (SMS) cell therapy aims to regenerate damaged alveolar lung tissue, it is currently being investigated for chronic obstructive pulmonary disease (COPD).

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 18, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank